This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.
Read More
New Formulation of Cabotegravir for HIV Treatment Can be Dosed at Intervals of at Least 4 Months
March 4th 2024In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.
Read More
A Strategy for Reducing STIs Through Implementing Doxycycline Post-Exposure Prophylaxis
March 4th 2024Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis
Read More
Changing the Antibiotic Reimbursement Model to Encourage Drug Development Proliferation
November 12th 2023Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.
Watch
IDWeek Chair: “Come up With the Best Program Possible”
October 14th 2023Heather Yun, MD, FACP, FIDS who is this year’s IDWeek Chair for the Infectious Diseases Society of America (IDSA) talks about the honor of the position, the collective effort to put together the conference, and offers insights on AMR during war, as well as new emerging infectious disease threats.
Watch